BioMarin Pharmaceutical Inc.BMRNNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank71
3Y CAGR+91.9%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
+91.9%/yr
vs -30.3%/yr prior
Acceleration
+122.2pp
Accelerating
Percentile
P71
Within normal range
vs 3Y Ago
7.1x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202523.39%
20240.06%
202314.96%
20223.31%
20210.11%
2020-12.15%
20192.68%
201814.01%
2017-7.73%
20164.27%